## BMRN: BioMarin Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.4% in lower entry zone (4.0-10.0%), top quartile (84th pct) cross-sectional ranking. Caution: MRS_5 (-1.0%) diverging from MRS_20, watch for reversal. Outperforming sector by 3.8%. Caution: declining volume (56% of avg), momentum weakening (-3.7% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($55.39)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. 19,329 Shares in BioMarin Pharmaceutical Inc. $BMRN Acquired by Financiere des Professionnels Fonds d investissement inc.**
- Source: MarketBeat | 20260104T110905 | Neutral | Relevance: 97%
- Financiere des Professionnels Fonds d investissement inc. recently acquired 19,329 shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) totaling approximately $1.05 million. This purchase is part of broader institutional investment, with institutional investors now owning close to 98.71% of the company's stock. BioMarin's recent financial results showed a miss on Q3 earnings expectations but analysts maintain a "Moderate Buy" rating with an average target price of $89.70.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-23 | Truist Securiti | $100 | $80 | +25% |
| 2025-12-22 | HC Wainwright & | $60 | $55 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-23 | Truist Securiti | main | Buy |
| 2025-12-22 | HC Wainwright & | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.91M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 11.5% (-8.1%)
- Vanguard Group Inc: 9.7% (-2.2%)
- Primecap Management : 7.9% (-3.4%)
- Dodge & Cox Inc.: 7.6% (-2.8%)
- State Street Corpora: 4.6% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.45 indicates undervaluation relative to growth. Forward P/E 11.1x attractive for 49% earnings growth. Quality metrics strong (margin 17%). Balance sheet: strong liquidity (4.8x), low leverage (D/E 0.26). Analyst sentiment positive (2 raises, avg +17%, $70 target (+19%)). Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.3B |
| Beta | 0.27 |
| 52W Range | $50.76 - $73.51 |
| Short Interest | 5.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.45 |
| Forward P/E | 11.1 |
| Current P/E | 16.5 |
| YoY Growth | 48.6% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from 8.1% to 4.4% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 84th percentile. MRS_5 (-1.0%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.5% shows strong absolute momentum above own 20MA. Outperforming sector by 3.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59. Volume at 56% of 20MA suggests lack of conviction. OFD pattern: -SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.39% (CS: 84) | Strong |
| RSI_14 | 58.7 | Neutral |
| MACD Histogram | 0.27 | Bullish |
| vs SMA20 | 1.045x | Above |
| vs SMA50 | 1.074x | Above |
| vs SMA200 | 1.025x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $58.87
- **Stop Loss:** $55.39 (5.9% risk)
- **Target:** $64.09 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 247
- **Position Value:** $14,540.89
- **Portfolio %:** 14.54%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-19 (Est: $0.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.34 | $0.12 | -64.3% |
| 2025Q2 | $1.03 | $1.44 | +39.4% |
| 2025Q1 | $0.95 | $1.13 | +18.6% |
| 2024Q4 | $0.74 | $0.92 | +24.6% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*